Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations

TL;DR

This paper reviews the challenges of using immunotherapy for melanoma in patients with weakened immune systems and highlights the need for better guidelines.

Contribution

The paper provides a comprehensive review of immunotherapy in immunocompromised melanoma patients and identifies gaps in current clinical management.

Findings

Immunotherapy can be effective in immunocompromised patients, but data is limited.

Standardized treatment algorithms for these patients are currently lacking.

Prospective trials or registries are recommended to improve management strategies.

Abstract

While immunotherapy has been widely adopted for the treatment of melanoma, its application in patients with complex comorbidities remains challenging. This review explores evidence on the efficacy, safety, and special considerations for the use of immunotherapy in patients with altered immune systems, including patients with human immunodeficiency virus (HIV), tuberculosis, solid organ or hematopoietic cell transplantation, autoimmune diseases, and pregnant women. Despite data emphasizing the feasibility of immunotherapy treatment in these populations, standardized management algorithms are lacking. Future research should consider either including these patients in prospective trials or attempting to collect data via registries to provide more clarity on the management of immunologically vulnerable patients with melanoma.